Cost-Effectiveness of Rifaximin-<i>α</i> versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis

<div>Meta-analysis of the cost-effectiveness of rifaximin-<i>α</i> plus lactulose compared with lactulose monotherapy in the second-line setting. A minimum of two studies are required to generate heterogeneity statistics (i.e. <svg height="11.6412pt" id="M10" style="vertical-align:-0.04979992pt" version="1.1" viewbox="-0.0498162 -11.5914 10.6309 11.6412" width="10.6309pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M405 650H141L135 622C222 616 230 610 215 535L133 116C118 41 113 33 29 28L23 0H289L295 28C209 33 205 40 219 116L298 535C312 609 317 616 399 622L405 650Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,5.567,-5.741)"><path d="M414 144C384 79 371 75 317 75H135L276 221C367 316 408 376 408 465C408 570 327 635 237 635C179 635 131 609 100 575L42 494L67 471C94 510 138 565 205 565C277 565 321 517 321 435C321 348 258 270 195 195C146 137 88 81 33 26V0H411C423 44 433 88 446 135L414 144Z"></path></g></svg> value or <svg height="8.68572pt" id="M11" style="vertical-align:-0.0498209pt" version="1.1" viewbox="-0.0498162 -8.6359 8.15071 8.68572" width="8.15071pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z"></path></g></svg> value); therefore, where only one study was available, these values could not be determined and were marked as not applicable (NA). Abbreviations: CI: confidence interval; DL: DerSimonian and Laird (random-effects model); <span class="nowrap"><svg height="11.6412pt" id="M12" style="vertical-align:-0.04979992pt" version="1.1" viewbox="-0.0498162 -11.5914 10.6309 11.6412" width="10.6309pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M405 650H141L135 622C222 616 230 610 215 535L133 116C118 41 113 33 29 28L23 0H289L295 28C209 33 205 40 219 116L298 535C312 609 317 616 399 622L405 650Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,5.567,-5.741)"><path d="M414 144C384 79 371 75 317 75H135L276 221C367 316 408 376 408 465C408 570 327 635 237 635C179 635 131 609 100 575L42 494L67 471C94 510 138 565 205 565C277 565 321 517 321 435C321 348 258 270 195 195C146 137 88 81 33 26V0H411C423 44 433 88 446 135L414 144Z"></path></g></svg>:</span> heterogeneity statistics; INB: incremental net benefit; IV: inverse variance; Lact: lactulose; <span class="nowrap"><svg height="8.68572pt" id="M13" style="vertical-align:-0.0498209pt" version="1.1" viewbox="-0.0498162 -8.6359 8.15071 8.68572" width="8.15071pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z"></path></g></svg>:</span> probability; Rif: rifaximin; US$: United States dollars.</div>

GastroHep

fig2

Figure 2

Figure 2: Cost-Effectiveness of Rifaximin-<i>α</i> versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis 

Figure 2 | Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis 